Joanna Roder

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial

Vanesa Gregorc, Silvia Novello, Chiara Lazzari et al. · The Lancet Oncology · 2014 · 158 citations · Full text

Prognostic Biomarkers, Medicine, Randomised Phase 3 +9

Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial

David P. Carbone, Keyue Ding, Heinrich Röder et al. · Journal of Thoracic Oncology · 2012 · 108 citations · Full text

A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma

Jeffrey S. Weber, Mario Sznol, Ryan J. Sullivan et al. · Cancer Immunology Research · 2017 · 72 citations · Full text

A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIIB/IV Non–Small-Cell Lung Cancer

Thomas E. Stinchcombe, Joanna Roder, Amy H. Peterman et al. · Journal of Thoracic Oncology · 2013 · 51 citations

Veristrat Status, Oncology, Elderly Patients +10

The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients

Mary J. Fidler, Cristina Fhied, Joanna Roder et al. · BMC Cancer · 2018 · 40 citations · Full text